摘要
目的:评价紫杉醇联合卡铂作为二线方案治疗进展期胃癌(AGC)的疗效及安全性。方法:回顾性分析27例一线治疗失败的AGC患者,以紫杉醇联合卡铂进行二线治疗,评价治疗后的客观有效率(RR)、疾病控制率(DC)、中位无进展生存时间(PFS)、中位生存时间(OS)及不良反应。结果:治疗后有27例可评价疗效,其中完全缓解0例,部分缓解7例(25.9%),稳定13例(48.2%),RR为25.9%,DC为74.1%,中位PFS、OS分别为4.8个月和9.3个月。主要不良反应为骨髓抑制、脱发。结论:紫杉醇联合卡铂二线治疗AGC,疗效肯定,且不良反应能够耐受。
OBJECTIVE：To evaluate the efficacy and safety of paclitaxel combined with carboplatin as second-line regimen in the treatment of advanced gastric cancer （AGC）.METHODS：27 AGC patients with first-line treatment failure received paclitaxel combined with carboplatin as second-line regimen.The objective response rate （RR）, disease control rate （DC）, median progression-free survival （PFS）, median survival time （OS） and ADR were evaluated.RESULTS：After treatment, 27 cases were evaluable for efficacy, of which 7 cases were partial remission （25.9%） and 13 cases stable （48.2%）, case complete remisson, RR was 25.9%, disease control rate was 74.1%, median PFS, OS were 4.8 and 9.3 months.The main ADR were myelosuppression and alopecia.CONCLUSION：Paclitaxel combined with carboplatin as second-line regimen has positive effect on AGC, and ADR can be tolerated.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第40期3797-3798,共2页
China Pharmacy
关键词
紫杉醇
卡铂
二线化疗
胃癌
Paclitaxel
Carboplatin
Second-line chemotherapy
Gastric cancer
